The effect of tobacco, XPC, ERCC2 and ERCC5 genetic variants in bladder cancer development by Kamel Rouissi et al.
RESEARCH ARTICLE Open Access
The effect of tobacco, XPC, ERCC2 and ERCC5
genetic variants in bladder cancer development
Kamel Rouissi1, Islem Ben Bahria1, Karim Bougatef1, Raja Marrakchi1, Nejla Stambouli1, Khouloud Hamdi1,
Mohamed Cherif2, Mohamed Riadh Ben Slama2, Mohamed Sfaxi2, Fethi Ben Othman2, Mohamed Chebil2,
Amel Benammar Elgaaied1, Slah Ouerhani3*
Abstract
Background: In this work, we have conducted a case-control study in order to assess the effect of tobacco and three
genetic polymorphisms in XPC, ERCC2 and ERCC5 genes (rs2228001, rs13181 and rs17655) in bladder cancer
development in Tunisia. We have also tried to evaluate whether these variants affect the bladder tumor stage and grade.
Methods: The patients group was constituted of 193 newly diagnosed cases of bladder tumors. The controls
group was constituted of non-related healthy subjects. The rs2228001, rs13181 and rs17655 polymorphisms were
genotyped using a polymerase chain reaction-restriction fragment length polymorphism technique.
Results: Our data have reported that non smoker and light smoker patients (1-19PY) are protected against bladder
cancer development. Moreover, light smokers have less risk for developing advanced tumors stage. When we
investigated the effect of genetic polymorphisms in bladder cancer development we have found that ERCC2 and
ERCC5 variants were not implicated in the bladder cancer occurrence. However, the mutated homozygous
genotype for XPC gene was associated with 2.09-fold increased risk of developing bladder cancer compared to the
control carrying the wild genotype (p = 0.03, OR = 2.09, CI 95% 1.09-3.99). Finally, we have found that the XPC,
ERCC2 and ERCC5 variants don’t affect the tumors stage and grade.
Conclusion: These results suggest that the mutated homozygous genotype for XPC gene was associated with
increased risk of developing bladder. However we have found no association between rs2228001, rs13181 and
rs17655 polymorphisms and tumors stage and grade.
Background
Bladder cancer incidence and mortality rates vary about
10-fold worldwide [1,2]. The highest rates are found in
North America and Western Europe, and are lower in
Eastern Europe and several parts of Asia [1]. Bladder
cancer is a smoking-related cancer [3]. Urothelial cell
carcinomas (UCC) represent more than 90% of bladder
tumors and are classified into superficial (pTa and pT1)
and muscle invasive (≥ pT2) stages. The majority of
superficial tumors recur but progression to muscle inva-
sion is relatively infrequent. Only high-grade superficial
tumors (pTa GIII and pT1 GIII) progress to invasive dis-
ease and represent a high-risk for death from disease [4].
Cigarette smoking is the predominant risk factor for
bladder cancer and is estimated to be responsible for 50%
of the cases in men, and 30% of the cases in women [3].
Cigarette smoke is a rich source of reactive oxygen spe-
cies that can induce a variety of DNA damage. The
body’s two primary defence mechanisms against muta-
genic exposure are DNA damage repair systems and
metabolic enzyme checkpoints [5]. Using these two
mechanisms facilitates cellular responses to DNA damage
from endogenous and exogenous mutagenic exposures to
maintain genomic integrity [5,6]. There are four major
DNA repair pathways in human cells: mismatch repair
(MMR), nucleotide-excision repair (NER), base-excision
repair (BER), and double-strand break (DSB) repair [6].
The damage caused by cigarette smoke is mainly removed
by the nucleotide- excision repair pathway, and to a lesser
extent, the base-excision repair pathway [7]. The NER
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pathway mainly removes bulky DNA adducts typically
generated from exposure to polycyclic aromatic hydrocar-
bons present in tobacco smoke. The BER pathway is
responsible for removal of oxidized DNA bases that may
arise endogenously or from exogenous agents [8].
The NER pathway has been reported to be the most
significant modulator of bladder cancer risk and impli-
cated many enzymes such as Xeroderma pigmentosum
type C, D and G (XPC, ERCC2 and ERCC5). The XPC
enzyme is an important DNA damage recognition pro-
tein that binds to damaged DNA at a very early stage
during DNA repair [9]. The ERCC5 (xeroderma pigmen-
tosum type G) protein is essential for the two incision
steps in nucleotide-excision repair [10]. The ERCC2
(xeroderma pigmentosum type D) protein takes part in
the nucleotide excision repair pathway, which recognizes
and repairs a wide range of structurally unrelated lesions
such as bulky adducts and thymidine dimers. This pro-
tein works as an ATP-dependent (5’—>3’) helicase joined
to the basal TFIIH complex to separate double helix [11].
Many polymorphisms were detected in XPC, ERCC2 and
ERCC5 genes and alter the ability of the encoded enzymes
to repair the DNA damage. These variants may increase
susceptibility to bladder cancer through complex gene-
gene and gene-smoking interactions [12]. Among variants
which were studied in association with bladder cancer we
note Lys939Gln genotype (A > C; rs2228001) in XPC gene,
Lys751Gln (rs13181) in ERCC2 gene and Asp1104His (G >
C; rs17655) in ERCC5 gene. Recently; many reported case-
control studies have analyzed the association between risk
factors (tobacco and NER genes polymorphisms) and blad-
der cancer development. However these studies have
reported conflicting results [12-17]. To the best of our
knowledge, no study has been done in Tunisia on the asso-
ciation among these 3 polymorphisms and the risk of blad-
der cancer. We hypothesized that these 3 polymorphisms
in three genes might contribute to the etiology of Bladder
cancer. To test this hypothesis, we genotyped Lys939Gln
genotype (A > C; rs2228001), ERCC2 Lys751Gln (rs13181)
and ERCC5 Asp1104His (G > C; rs17655) polymorphisms
in our ongoing hospital-based case-control study of Blad-
der cancer in a population from Tunisia. We have also try
to evaluate whether these studied single nucleotide poly-
morphisms (SNP) affect tumors phenotypes by investigat-




This study was approved by a local ethical committee.
After giving informed consent, the demographic details
were obtained by interviewing each subject and periph-
eral blood samples were collected from all subjects into
tubes with EDTA at pH 8. A total of 193 patients with
urothelial cell carcinoma of bladder cancer and 193 con-
trol subjects were included in the present study. The
controls were recruited daily from patients newly diag-
nosed and treated at the same urology department for
benign diseases, mainly prostatic hyperplasia, cystitis
and urolithiasis. Patients with cancer, or liver or renal
diseases, were excluded. This control group was consti-
tuted of non-related subjects who were matched to the
case group for sex proportion, geographic origin, and
age range. Patients were recruited from the Department
of Urology at the Charles Nicole Hospital in Tunisia. All
were from the North of Tunisia, 91.2% of them were
men, and the mean age at diagnosis was 65.23 ±11.3
years. These patients were classified according to their
tobacco status. The smoker category included current
smokers who smoked daily. Non consumers of tobacco
were defined as persons who had never smoked or had
consumed less than 20 packs of cigarettes or 360 g of
tobacco in their lifetime or less than one cigarette per
day. The intensity of tobacco use (PY) was defined as
the amount of tobacco consumed during the life of
patients (1 PY = 7300 cigarettes smoked during 1 year).
It was found that 79.79% (154/193) of patients were cur-
rent smokers, and 20.21% were non-tobacco consumers.
The clinical characteristics, including tumor stage and
grade, were obtained from the urologist of our depart-
ment. Tumors were staged according to the criteria of
the tumor-node-metastasis classification (TNM) and the
WHO-International Society of Urological Pathology as
follows: 13 carcinoma in Situ (CIS), 34 pTa GI, 12 pTa
GII, 3 pTa GIII, 53 pT1 GII, 34 pT1 GIII and 44 inva-
sive tumors (≥ pT2).
DNA preparation and genotyping
Genomic DNA was extracted from leukocytes using a
phenol-chloroform procedure [18]. The quality of geno-
mic DNA was controlled by electrophoresis on a 1%
agarose gel stained with ethidium bromide. The XPC,
ERCC2 and ERCC5 polymorphisms were detected with
polymerase chain reaction-restriction fragment length
polymorphism-based approaches (PCR-RFLP), as
described previously [19]. The studied polymorphisms
and details of RFLPs are shown in Table 1.
Statistical analysis
Departures from Hardy-Weinberg equilibrium were
tested using the software package Arlequin ver 3.01 [20].
We have used Epi info 6.0 software to calculate the odds
ratios (OR) value with 95% confidence intervals (CI). We
have also used the logistic regression test of SPSS 16.0
software to investigate the impact of smoking and poly-
morphisms in repair genes on the development and pro-
gression of bladder cancer. The logistic regression is a
mathematical modelling approach that is used to describe
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the relationship of several predictor variables X1, X2,...,
Xk to a dichotomous dependent variable Y which is typi-
cally coded as 1 or 0 for its two possible categories.
Results
Genotype and gene distributions for ERCC2, XPC and
ERCC5 in 193 bladder cancer cases and 193 controls
are summarized in Table 2. All samples were found to
be in Hardy-Weinberg equilibrium, except for cases of
XPC A > C polymorphism, among whom the genotypic
distribution showed statistical differences from Hardy-
Weinberg expectations (P = 0.008).
Effect of tobacco and genetic polymorphisms of XPC,
ERCC2 and ERCC5 in bladder cancer development
By using logistic regression test we have found that non
smokers and light smokers (1-19PY) were protected
against bladder cancer development (Table 3). The
XPC*C, ERCC2*C and ERCC5*C variants were respec-
tively detected at 35.23%, 33.16% and 32.64% of controls
group. The comparison of patients and controls accord-
ing to the frequencies of ERCC2 and ERCC5 genotypes
did not show a significant statistic difference (Table 2).
However, significant differences in genotypic frequencies
were detected for the XPC A > C polymorphism.
Indeed, the XPC C/C genotype was found to be at a sig-
nificant 2.09-fold significant increased risk of developing
bladder cancer compared to the control carrying the
wild genotype (Table 2). In fact, the logistic regression
casts a protective effect of XPC AA and AC genotype
against bladder cancer development (Table 3).
Effect of tobacco, XPC, ERCC2 and ERCC5 polymorphisms
on tumors stage and grade
Tumors were staged according to the criteria of the
tumor-node-metastasis classification (TNM) and the
Table 1 Details of RFLPs studied
Gene/exon Polymorphism (amino acid change) SNP reference Genotype PCR product sizes (Pb) Restriction enzyme
XPC exon 16 A > C (Lys939Gln) rs2228001 AA
AC 244 PvuII
CC
ERCC2 exon 23 A > C (Lys751Gln) rs13181 AA
AC 348 PstI
CC
ERCC5 exon 15 G > C (Asp1104His) rs17655 GG
GC 158 Hsp92II
CC
Table 2 Comparisons of the XPC, ERCC2 and ERCC5 alleles and genotypes distributions between patients and controls
N (%)
Alleles and Genotypes Controls (N = 193) Patients (N = 193) P value OR (95% CI)
XPC (rs2228001)
AA 79 (40.9) 74 (38.3) - 1*
AC 92 (47.7) 76 (39.4) 0.65 -
CC 22 (11.4) 43 (22.3) 0.04** 2.09 (1.09-3.99)
A 250 (64.8) 224 (58.0) - 1*
C 136 (35.2) 162 (42.0) 0.06 -
ERCC2 (rs13181)
AA 86 (44.6) 97 (50.3) - 1*
AC 86 (44.6) 76 (39.4) 0.30 -
CC 21 (10.9) 20 (10.4) 0.75 -
A 258 (66.8) 270 (69.9) - 1*
C 128 (33.2) 116 (30.1) 0.39 -
ERCC5 (rs17655)
GG 87 (45.1) 95 (49.2) - 1*
GC 86 (44.6) 70 (36.3) 0.21 -
CC 20 (10.4) 28 (14.5) 0.55 -
G 260 (67.3) 260 (67.3) - 1*
C 126 (32.7) 126 (32.7) 0.93 -
95% CI: Confidence Interval, 1*: reference group, **: Corrected p value (Bonferroni’s correction).
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WHO-International Society of Urological Pathology as
follows: 49 pTa, 87 pT1 and 44 invasive tumors (≥ pT2).
The comparison of patients with advanced tumors
stages to the reference group (pTa) according to genetic
polymorphisms dose not show a significant difference
(Table 4). The same result was obtained when we stu-
died the effect of genetic polymorphisms on the grade
of pT1 tumors group (Table 5). However, we have
reported that the risk of developing pT1 tumors
decrease significantly on light smokers (p = 0.03, OR =
0.15; CI 95% = 0.027-0.882). We have also found that
non-smoker patients with pT1 have at a 6.88-fold signif-
icant increased risk of developing a GIII grade compared
to the reference group (Table 5).
Discussion
Bladder cancer is strongly related to occupational and
environmental exposure to chemical carcinogens.
Cigarette smoking is nevertheless responsible for more
cases of bladder cancer than any other risk factors
because of its high prevalence [3]. The damage caused
by cigarette smoke is mainly removed by the nucleotide-
excision repair pathway (NER), and to a lesser extent,
the base-excision repair pathway [7]. In this population-
based case-control study we investigated the effect of
tobacco and gene repair polymorphisms on bladder can-
cer development and their association with tumors stage
and grade.
By using logistic regression test we have found that non
smokers and light smokers (1-19PY) were protected
against bladder cancer development. This result confirms
the idea which considered tobacco as the most important
exogenous risk factor for bladder cancer [3]. Tobacco
components, such as 4-aminobiphenyl (4-ABP), increase
bladder cancer risk by inducing local somatic mutations.
Indeed, the study of Feng et al. [21] has reported that
cigarette smoke generates a substantial amount of 4-ABP
and metabolically activated 4-ABP preferentially binds to
codons 280 and 285 of the p53 gene. Moreover, Ouer-
hani et al. [22] have reported that the p53 and FGFR3
spectral mutations, which were the most frequent
mutated genes in bladder cancer, appears to depend to
the intensity of tobacco use (PY). When we studied the
association between tobacco and tumors stages our data
have reported that the risk of developing pT1 tumors
decrease significantly on light smokers (p = 0.036, OR =
0.154; CI 95% = 0.027-0.882). This result confirms the
study of Thompson et al. [23] who have suggested that
bladder tumors in patients who smoke tend to be large,
multifocal and demonstrate high-histological stage. In
contrast, we have found that non-smoker patients with
pT1 have at a significant 6.88-fold increased risk of devel-
oping a GIII grade compared to the reference group. Our
hypothesis suggests that tobacco is not implicated on the
determination of the tumors grade.
The alleles frequencies for XPC*C, ERCC2*C and
ERCC5*C, in control group were estimated at 0.352,
0.331 and 0.326 respectively. These frequencies were dif-
ferent to which reported for the Caucasian populations.
Indeed, Goode et al. [24] have reported the frequencies
of 0.38 and 0.23 for the ERCC2*C and ERCC5*C var-
iants. In fact Mechanic et al. [25] and Agalliu et al. [26]
Table 3 Case-control study: implication of tobacco and polymorphisms in XPC, ERCC2 and ERCC5 on bladder cancer
development
95% Confidence Interval for Exp(B)
groupa B Standard error Wald Df P value Exp (B) = OR Lower Bound Upper Bound
Cases Intercept -1,10 1,08 1,03 1 ,31
Sex ,30 ,42 ,53 1 ,46 1,36 ,59 3,11
Age range 1,82 ,39 21,99 1 ,00 6,22 2,89 13,35
[XPC (A/C) = AA] -,85 ,34 6,06 1 ,01 ,42 ,21 ,84
[XPC (A/C) = AC] -1,01 ,34 8,80 1 ,00 ,36 ,18 ,70
[XPC (A/C) = CC] 0b . . 0 . . . .
[ERCC2 (A/C) = AA] ,12 ,40 ,10 1 ,75 1,13 ,51 2,51
[ERCC2 (A/C) = AC] -,16 ,40 ,15 1 ,69 ,85 ,38 1,90
[ERCC2 (A/C) = CC] 0b . . 0 . . . .
[ERCC5 (G/C) = CC] ,55 ,38 2,11 1 ,14 1,74 ,82 3,71
[ERCC5 (G/C) = GC] -,22 ,24 ,85 1 ,35 ,79 ,49 1,29
[ERCC5 (G/C) = GG] 0b . . 0 . . . .
[Tobacco PY = 0] -1,18 ,32 13,03 1 ,00 ,30 ,16 ,58
[Tobacco PY = 1-19] -1,97 ,45 19,17 1 ,00 ,13 ,05 ,33
[Tobacco PY ≥ 20] 0b . . 0 . . . .
This reduced model was obtained after adjustment to sex and age; a: The reference category is controls group; b: this parameter is set to zero because it is
redundant; PY: pack years. Logistic regression: Number of observation = 386, Chi-square: 88.409, p = 0.000, Pseudo R-square = 0.205, Log likelihood = 206,541.
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have reported that the frequencies of XPC*C, ERCC2*C
and ERCC5*C, in control group were respectively esti-
mated at 0.39/0.48, 0.36 and 0.23/0.45. The comparison
of patients and controls according to XPC A > C poly-
morphism have showed that patients harboring XPC C/
C genotype was associated with a significant 2.09-fold
increased risk of developing bladder cancer compared to
the control carrying the wild genotype. This results con-
firm the recent study of de Verdier et al. [27] who have
found an association with the K939Q (A > C) poly-
morphism and bladder-cancer. This association is
explained by the fact that Xeroderma pigmentosum type
C (XPC), a NER gene, is considered as an important
DNA damage recognition protein that binds to damaged
DNA at a very early stage during DNA repair binds [9].
The NER pathway mainly removes bulky DNA adducts,
which are typically generated from exposure to polycyclic
aromatic hydrocarbons in tobacco smoke. Therefore, the
NER pathway would be expected to play a more signifi-
cant role in repairing tobacco carcinogen-induced DNA
damage, whereas the other DNA-repair pathways play a
less prominent role. However, although this polymorph-
ism replaces the basic, hydrophilic amino acid lysine with
the neutral amino acid glutamine, the risk association, as
well as the functional consequences, remain controversial
[28,29].
The comparison of patients and controls according to
the frequencies of ERCC2 genotypes does not show a sig-
nificant statistic difference. Our observation of no associa-
tion of the XPD Lys751Gln genotypes with the risk of
Bladder cancer is compatible with the findings from Shen
et al. [13] and Gangwar et al. [30] who reported no asso-
ciation of the ERCC2 codon 751 polymorphism with blad-
der cancer risk. However, Gao et al. [16] and Li et al. [17]
Table 4 Logistic regression: effect of tobacco and XPC, ERCC2 and ERCC5 polymorphisms on tumors stages
95% Confidence Interval for Exp(B)
stade a B Std. Error Wald Df Sig. Exp(B) Lower Bound Upper Bound
Pt1 Intercept -,55 1,80 ,09 1 ,75
Sex ,97 ,78 1,54 1 ,21 2,64 ,57 12,20
Age -1,16 ,47 6,06 1 ,01 ,31 ,12 ,78
[XPC (A/C) = AA] -,11 ,53 ,04 1 ,82 ,89 ,31 2,53
[XPC (A/C) = AC] ,49 ,54 ,83 1 ,36 1,64 ,56 4,74
[XPC (A/C) = CC] 0b . . 0 . . . .
[ERCC2 (A/C) = AA] ,66 ,64 1,07 1 ,30 1,94 ,55 6,84
[ERCC2 (A/C) = AC] ,24 ,65 ,13 1 ,71 1,27 ,35 4,56
[ERCC2 (A/C) = CC] 0b . . 0 . . . .
[ERCC5 (G/C) = CC] ,64 ,65 ,99 1 ,31 1,91 ,53 6,82
[ERCC5(G/C) = GC] ,25 ,41 ,36 1 ,54 1,28 ,57 2,87
[ERCC5(G/C) = GG] 0b . . 0 . . . .
[PY = 0] ,20 ,56 ,13 1 ,71 1,22 ,40 3,72
[PY = 1-19] -1,87 ,89 4,41 1 ,03 ,15 ,02 ,88
[PY ≥ 20] 0b . . 0 . . . .
≥pT2 Intercept -,62 3,04 ,04 1 ,83
Sex 1,27 1,41 ,81 1 ,36 3,58 ,22 57,00
Age -1,71 ,63 7,22 1 ,00 ,18 ,05 ,63
[XPC(A/C) = AA] -,42 ,59 ,51 1 ,47 ,65 ,20 2,10
[XPC(A/C) = AC] -,19 ,62 ,09 1 ,75 ,82 ,24 2,77
[XPC(A/C) = CC] 0b . . 0 . . . .
[ERCC2(A/C) = AA] ,65 ,80 ,67 1 ,41 1,93 ,40 9,29
[ERCC2(A/C) = AC] ,34 ,80 ,18 1 ,67 1,40 ,29 6,81
[ERCC2(A/C) = CC] 0b . . 0 . . . .
[ERCC5(G/C) = CC] 1,02 ,71 2,07 1 ,14 2,79 ,69 11,33
[ERCC5(G/C) = GC] -,16 ,50 ,10 1 ,74 ,84 ,31 2,29
[ERCC5(G/C) = GG] 0b . . 0 . . . .
[PY = 0] -1,21 ,88 1,87 1 ,17 ,29 ,05 1,69
[PY = 1-19] -2,24 1,16 3,72 1 ,05 ,10 ,01 1,03
[PY ≥ 20] 0b . . 0 . . . .
This model was obtained after adjustment to sex and age; a: The reference category is Pta tumor group; b: this parameter is set to zero because it is redundant;
PY: pack years. Logistic regression: Number of observation = 193, Chi-square: 32.851, p = 0.035, Pseudo R-square = 0.087, Log likelihood = 187,948.
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suggest that individuals who have the ERCC2 751Gln
allele may be at an increased risk for bladder cancer.
Authors explain this association by the fact that ERCC2
gene mutations can diminish the activity of TFIIH com-
plexes giving rise to repair defects, transcription defects,
and abnormal responses to apoptosis [31]. With regarding
the ERCC5 Asp1104His polymorphism we confirm the
study of Sanyal et al. [15] whom don’t found a significant
difference for genotype distributions between the bladder
cancer cases and the controls.
The comparison of patients according to the clinical
characteristics does not show a significant association
between XPC, ERCC2 or ERCC5 polymorphisms and
tumors stage and grade. Our results is compatible with the
findings from Gangwar et al. [30] who reported no asso-
ciation of the ERCC2 codon 751 polymorphism with any
stage and grade However, Chen et al. [12] have reported
strong correlation of XPC deficiency, and the degree of
malignancy of bladder tumors. This association is
explained by the great correlation between XPC deficiency
and p53 mutations. Indeed, the p53 alterations occur pre-
dominantly in invasive and high-grade superficial tumors
[32]. Moreover Sakano et al. [33] have reported that the
Asp1104His polymorphism in exon 15 of ERCC5
(rs17655) was associated with tumour stage and grade at
presentation, especially in the subgroups divided by age.
This association is explained by the fact that the
Asp1104His polymorphism which was located in the
ERCC5 C-terminus, is required for interactions with the
transcription factor TFIIH in the incision complex of NER.
Although some of the results presented here are novel,
this study has some limitations. Firstly, the sample size is
small, limiting the precision of the statistical analyses.
Secondly, the correlation between XPC C/C genotype
and cell cycle gene alterations (such as p53) was not
done. This correlation is very interesting to understand
the mechanism of action of XPC on bladder cancer
initiation. Besides that in the future, enlargement of sam-
ple sizes in the Tunisian population and analysis of
somatic altered genes (which is already ongoing) will be
essential to assess the role that environmental factors
together with the genetic factors play as predictors of dif-
ferential susceptibility to the presentation of malignancy.
Conclusion
In this study we find statistical evidence from general-
ized ordered logistic models that non smokers and light
smoker patients (1-19PY) are protected against bladder
cancer development and invasiveness. Our results also
indicate that patients with XPC C/C genotype were at
increased risk for developing bladder cancer. Finally, we
have reported that the SNP in the XPC, ERCC2 and
ERCC5 genes don’t affect the bladder tumors phenotype.
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